SE9404468D0 - Powder formulations - Google Patents

Powder formulations

Info

Publication number
SE9404468D0
SE9404468D0 SE9404468A SE9404468A SE9404468D0 SE 9404468 D0 SE9404468 D0 SE 9404468D0 SE 9404468 A SE9404468 A SE 9404468A SE 9404468 A SE9404468 A SE 9404468A SE 9404468 D0 SE9404468 D0 SE 9404468D0
Authority
SE
Sweden
Prior art keywords
powder formulations
medically useful
formulation
polypeptide
useful polypeptide
Prior art date
Application number
SE9404468A
Other languages
English (en)
Swedish (sv)
Inventor
Kjell Baeckstroem
Ann Johansson
Helena Linden
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9404468A priority Critical patent/SE9404468D0/xx
Publication of SE9404468D0 publication Critical patent/SE9404468D0/xx
Priority to ZA9510753A priority patent/ZA9510753B/xx
Priority to PT95942342T priority patent/PT799030E/pt
Priority to NZ298168A priority patent/NZ298168A/en
Priority to IL11645995A priority patent/IL116459A/en
Priority to ES01130870T priority patent/ES2222306T3/es
Priority to PT01130870T priority patent/PT1224929E/pt
Priority to DK95942342T priority patent/DK0799030T3/da
Priority to EP95942342A priority patent/EP0799030B1/en
Priority to DK01130870T priority patent/DK1224929T3/da
Priority to UA97073876A priority patent/UA44757C2/uk
Priority to CN95196965A priority patent/CN1080114C/zh
Priority to DE69533294T priority patent/DE69533294T2/de
Priority to CA002206803A priority patent/CA2206803A1/en
Priority to US08/617,753 priority patent/US6004574A/en
Priority to AU43592/96A priority patent/AU702898B2/en
Priority to EE9700135A priority patent/EE03381B1/xx
Priority to ES95942342T priority patent/ES2177674T3/es
Priority to JP8519731A priority patent/JPH10510828A/ja
Priority to BR9510422A priority patent/BR9510422A/pt
Priority to RU97112496A priority patent/RU2144819C1/ru
Priority to DE69527542T priority patent/DE69527542T2/de
Priority to HU9800493A priority patent/HU217975B/hu
Priority to AT01130870T priority patent/ATE271382T1/de
Priority to PCT/SE1995/001541 priority patent/WO1996019207A1/en
Priority to PL95320751A priority patent/PL183944B1/pl
Priority to MYPI95003942A priority patent/MY114211A/en
Priority to TW084113557A priority patent/TW474823B/zh
Priority to AT95942342T priority patent/ATE220900T1/de
Priority to CZ19971946A priority patent/CZ288487B6/cs
Priority to SK812-97A priority patent/SK283147B6/sk
Priority to EP01130870A priority patent/EP1224929B1/en
Priority to KR1019970704254A priority patent/KR100391873B1/ko
Priority to ARP950100706A priority patent/AR002261A1/es
Priority to TR95/01632A priority patent/TR199501632A1/tr
Priority to SA95160484A priority patent/SA95160484B1/ar
Priority to IS4495A priority patent/IS1848B/is
Priority to NO19972660A priority patent/NO315966B1/no
Priority to MXPA/A/1997/004551A priority patent/MXPA97004551A/xx
Priority to FI972654A priority patent/FI972654A/fi
Priority to HK98102788A priority patent/HK1003619A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
SE9404468A 1994-12-22 1994-12-22 Powder formulations SE9404468D0 (sv)

Priority Applications (41)

Application Number Priority Date Filing Date Title
SE9404468A SE9404468D0 (sv) 1994-12-22 1994-12-22 Powder formulations
ZA9510753A ZA9510753B (en) 1994-12-22 1995-12-18 Power formulations
RU97112496A RU2144819C1 (ru) 1994-12-22 1995-12-19 Порошкообразные препараты, содержащие мелецитозу в качестве разбавителя
JP8519731A JPH10510828A (ja) 1994-12-22 1995-12-19 賦形剤としてメレチトースを含む粉末製剤
SK812-97A SK283147B6 (sk) 1994-12-22 1995-12-19 Práškový prostriedok na aplikáciu liečivých peptidov, spôsob jeho výroby a jeho použitie
IL11645995A IL116459A (en) 1994-12-22 1995-12-19 Powdery preparations containing a medically effective polypeptide, and a method for their preparation
ES01130870T ES2222306T3 (es) 1994-12-22 1995-12-19 Formulaciones en polvo que contienen melezitosa como diluyente.
PT01130870T PT1224929E (pt) 1994-12-22 1995-12-19 Formulacoes em po contendo melezitose como diluente
DK95942342T DK0799030T3 (da) 1994-12-22 1995-12-19 Pulverformuleringer indeholdende melezitose som fortyndingsmiddel
EP95942342A EP0799030B1 (en) 1994-12-22 1995-12-19 Powder formulations containing melezitose as a diluent
DK01130870T DK1224929T3 (da) 1994-12-22 1995-12-19 Pulverformuleringer indeholdende melezitose som et fortyndingsmiddel
UA97073876A UA44757C2 (uk) 1994-12-22 1995-12-19 Порошкоподібний препарат для введення медично корисних поліпептидів шляхом інгаляції, спосіб виробництва порошкоподібного препарату та спосіб лікування пацієнта
CN95196965A CN1080114C (zh) 1994-12-22 1995-12-19 含有松三糖作为稀释剂的粉剂
DE69533294T DE69533294T2 (de) 1994-12-22 1995-12-19 Pulverformulierungen, die Melezitose als Verdünnungsmittel enthalten
CA002206803A CA2206803A1 (en) 1994-12-22 1995-12-19 Powder formulations containing melezitose as a diluent
US08/617,753 US6004574A (en) 1994-12-22 1995-12-19 Powder formulations containing melezitose as a diluent
HU9800493A HU217975B (hu) 1994-12-22 1995-12-19 Polipeptidet higítóként melezitózt tartalmazó inhalációs porkészítmények és eljárás előállításukra
EE9700135A EE03381B1 (et) 1994-12-22 1995-12-19 Pulbrilised ravimvormid, mis sisaldavad lahjendajana melesitoosi
ES95942342T ES2177674T3 (es) 1994-12-22 1995-12-19 Formulaciones de polvos que contienen melezitosa como un diluyente.
PT95942342T PT799030E (pt) 1994-12-22 1995-12-19 Formulacoes em po contendo melezitose como diluente
BR9510422A BR9510422A (pt) 1994-12-22 1995-12-19 Formulação em pó para administração de polipeptídeos medicamente úteis uso do pó e processos para fabricação da formulação e para tratamento de um paciente carente de terapia
DE69527542T DE69527542T2 (de) 1994-12-22 1995-12-19 Pulverformulierungen die melizitose als verdünnungsmittel enthalten
KR1019970704254A KR100391873B1 (ko) 1994-12-22 1995-12-19 희석제로서멜레지토스를함유하는분말제제
AU43592/96A AU702898B2 (en) 1994-12-22 1995-12-19 Powder formulations containing melezitose as a diluent
AT01130870T ATE271382T1 (de) 1994-12-22 1995-12-19 Pulverformulierungen, die melezitose als verdünnungsmittel enthalten
PCT/SE1995/001541 WO1996019207A1 (en) 1994-12-22 1995-12-19 Powder formulations containing melezitose as a diluent
PL95320751A PL183944B1 (pl) 1994-12-22 1995-12-19 Preparaty proszkowe przydatnych medycznie polipeptydów i sposób ich wytwarzania
MYPI95003942A MY114211A (en) 1994-12-22 1995-12-19 Powder formulations containing melezitose as a diluent
TW084113557A TW474823B (en) 1994-12-22 1995-12-19 Powder formulations containing, as a diluent, D-melezitose (Α-D-melezitose), β-D-glucopyranoside, O-Α-D-glucopyranosyl-1,3-β-D-fructofuranosyl (β-D-melezitose) or isomelezitose
AT95942342T ATE220900T1 (de) 1994-12-22 1995-12-19 Pulverformulierungen die melizitose als verdünnungsmittel enthalten
CZ19971946A CZ288487B6 (en) 1994-12-22 1995-12-19 Powder formulation for the administration of medically useful polypeptides and process for preparing thereof
NZ298168A NZ298168A (en) 1994-12-22 1995-12-19 Powdered medicaments for administering polypeptides; contain melezitose as diluent
EP01130870A EP1224929B1 (en) 1994-12-22 1995-12-19 Powder formulations containing melezitose as a diluent
TR95/01632A TR199501632A1 (tr) 1994-12-22 1995-12-21 Toz formülasyonlari.
ARP950100706A AR002261A1 (es) 1994-12-22 1995-12-21 Composicion en polvo para la administracion por inhalacion de polipeptidos utiles en medicina, metodos para la manufactura de dicha composicion, y uso de la composicion para la manufactura de un medicamento para el tratamietno de enfermedades a traves del tracto respiratorio
SA95160484A SA95160484B1 (ar) 1994-12-22 1995-12-30 مستحضرات مساحيق تحتوي على مليزيتوز melezitose كمادة مخففة
IS4495A IS1848B (is) 1994-12-22 1997-06-03 Duftblöndur sem innihalda melesítósa sem þynningarefni
NO19972660A NO315966B1 (no) 1994-12-22 1997-06-10 Pulverformulering inneholdende melezitose som et fortynningsmiddel, fremgangsmåter for dens fremstilling, og anvendelse derav
MXPA/A/1997/004551A MXPA97004551A (en) 1994-12-22 1997-06-18 Formulations in powder containing melecitose as a diluye
FI972654A FI972654A (fi) 1994-12-22 1997-06-19 Meletsitoosia laimentimena sisältävät jauhekoostumukset
HK98102788A HK1003619A1 (en) 1994-12-22 1998-04-02 Powder formulations containing melezitose as a diluent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9404468A SE9404468D0 (sv) 1994-12-22 1994-12-22 Powder formulations

Publications (1)

Publication Number Publication Date
SE9404468D0 true SE9404468D0 (sv) 1994-12-22

Family

ID=20396435

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9404468A SE9404468D0 (sv) 1994-12-22 1994-12-22 Powder formulations

Country Status (34)

Country Link
US (1) US6004574A (tr)
EP (2) EP0799030B1 (tr)
JP (1) JPH10510828A (tr)
KR (1) KR100391873B1 (tr)
CN (1) CN1080114C (tr)
AR (1) AR002261A1 (tr)
AT (2) ATE220900T1 (tr)
AU (1) AU702898B2 (tr)
BR (1) BR9510422A (tr)
CA (1) CA2206803A1 (tr)
CZ (1) CZ288487B6 (tr)
DE (2) DE69527542T2 (tr)
DK (2) DK1224929T3 (tr)
EE (1) EE03381B1 (tr)
ES (2) ES2222306T3 (tr)
FI (1) FI972654A (tr)
HK (1) HK1003619A1 (tr)
HU (1) HU217975B (tr)
IL (1) IL116459A (tr)
IS (1) IS1848B (tr)
MY (1) MY114211A (tr)
NO (1) NO315966B1 (tr)
NZ (1) NZ298168A (tr)
PL (1) PL183944B1 (tr)
PT (2) PT799030E (tr)
RU (1) RU2144819C1 (tr)
SA (1) SA95160484B1 (tr)
SE (1) SE9404468D0 (tr)
SK (1) SK283147B6 (tr)
TR (1) TR199501632A1 (tr)
TW (1) TW474823B (tr)
UA (1) UA44757C2 (tr)
WO (1) WO1996019207A1 (tr)
ZA (1) ZA9510753B (tr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6632456B1 (en) * 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
MX9704550A (es) * 1994-12-22 1997-10-31 Astra Ab Formulaciones de medicamentos en aerosol.
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
AU6611998A (en) * 1997-03-20 1998-10-20 Novo Nordisk A/S Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
WO2000061178A1 (en) * 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
JP2002541213A (ja) 1999-04-13 2002-12-03 インヘール セラピューティック システムズ， インコーポレイテッド 不妊症の処置のための乾燥粉末処方物の肺投与
GB0011807D0 (en) * 2000-05-16 2000-07-05 Quadrant Holdings Cambridge Formulation for inhalation
AU8111301A (en) * 2000-08-07 2002-02-18 Inhale Therapeutic Syst Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
MXPA04004726A (es) 2001-11-19 2004-07-30 Becton Dickinson Co Composiciones farmaceuticas en forma particulada.
SE0200657D0 (sv) * 2002-03-04 2002-03-04 Astrazeneca Ab Novel Formulation
CN105801686B (zh) 2004-07-19 2020-04-07 比奥孔有限公司 胰岛素-低聚物共轭物、制剂及其用途
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
WO2006025882A2 (en) * 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
EP2203181B1 (en) 2007-10-16 2018-02-14 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
ES2586032T3 (es) 2008-03-28 2016-10-11 Hale Biopharma Ventures, Llc Administración de composiciones de benzodiazepinas
CN101618023B (zh) * 2008-06-30 2011-11-30 江苏先声药物研究有限公司 一种制备微粉化蛋白的方法
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
ES2545893T3 (es) 2010-04-20 2015-09-16 Octapharma Ag Nuevo agente estabilizante para proteínas farmacéuticas
WO2012174158A2 (en) 2011-06-14 2012-12-20 Hale Biopharma Ventures, Llc Administration of benzodiazepine
US9480966B2 (en) * 2012-04-30 2016-11-01 General Electric Company Substrates and methods for collection, stabilization and elution of biomolecules
US11324763B2 (en) * 2014-03-25 2022-05-10 National University Corporation Kagawa University Malaria transmission prevention agent having rare sugar as effective component thereof and malarial parasite growth regulating agent
CN106572690A (zh) * 2014-06-30 2017-04-19 泰特及莱尔组分美国公司 用于消耗品的涂层组合物
CN107106641B (zh) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 粉末制剂
CN108473932B (zh) 2015-09-09 2022-07-15 集联健康有限公司 用于样品收集、稳定化和保存的系统、方法和装置
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE556587A (tr) * 1957-01-31 1957-04-11
GB1144905A (en) * 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
SE7812207L (sv) * 1977-12-01 1979-06-02 Welsh Nat School Med Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
DE3326089A1 (de) * 1983-07-20 1985-02-07 Gödecke AG, 1000 Berlin Zur inhalation bestimmte darreichungsform von calcium-antagonisten
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
WO1986006959A1 (en) * 1985-05-22 1986-12-04 Liposome Technology, Inc. Liposome inhalation method and system
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
EP0360340A1 (en) * 1988-09-19 1990-03-28 Akzo N.V. Composition for nasal administration containing a peptide
JPH02104531A (ja) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
AU643141B2 (en) * 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
ATE146359T1 (de) * 1992-01-21 1997-01-15 Stanford Res Inst Int Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
ATE220327T1 (de) * 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband

Also Published As

Publication number Publication date
KR100391873B1 (ko) 2003-10-17
IS1848B (is) 2003-02-07
US6004574A (en) 1999-12-21
ATE220900T1 (de) 2002-08-15
AR002261A1 (es) 1998-03-11
EE03381B1 (et) 2001-04-16
DE69533294D1 (de) 2004-08-26
PT1224929E (pt) 2004-10-29
SK81297A3 (en) 1997-11-05
CZ194697A3 (en) 1997-10-15
EP1224929A3 (en) 2002-12-18
JPH10510828A (ja) 1998-10-20
DE69527542D1 (de) 2002-08-29
ES2177674T3 (es) 2002-12-16
WO1996019207A1 (en) 1996-06-27
SA95160484B1 (ar) 2005-10-01
EP0799030A1 (en) 1997-10-08
IS4495A (is) 1997-06-03
DK1224929T3 (da) 2004-10-04
CA2206803A1 (en) 1996-06-27
CN1080114C (zh) 2002-03-06
ZA9510753B (en) 1996-06-24
EP0799030B1 (en) 2002-07-24
DE69527542T2 (de) 2003-01-30
BR9510422A (pt) 1998-07-07
FI972654A0 (fi) 1997-06-19
NZ298168A (en) 1999-08-30
EP1224929A2 (en) 2002-07-24
CN1171049A (zh) 1998-01-21
TR199501632A1 (tr) 1997-03-21
AU702898B2 (en) 1999-03-11
MX9704551A (es) 1997-10-31
RU2144819C1 (ru) 2000-01-27
SK283147B6 (sk) 2003-03-04
NO972660D0 (no) 1997-06-10
EE9700135A (et) 1997-12-15
CZ288487B6 (en) 2001-06-13
HK1003619A1 (en) 1998-11-06
HU217975B (hu) 2000-05-28
ES2222306T3 (es) 2005-02-01
PL320751A1 (en) 1997-10-27
FI972654A (fi) 1997-06-19
IL116459A0 (en) 1996-03-31
TW474823B (en) 2002-02-01
PT799030E (pt) 2002-11-29
HUT77648A (hu) 1998-07-28
NO315966B1 (no) 2003-11-24
AU4359296A (en) 1996-07-10
EP1224929B1 (en) 2004-07-21
PL183944B1 (pl) 2002-08-30
IL116459A (en) 2002-11-10
DE69533294T2 (de) 2005-05-19
ATE271382T1 (de) 2004-08-15
MY114211A (en) 2002-08-30
UA44757C2 (uk) 2002-03-15
DK0799030T3 (da) 2002-09-16
NO972660L (no) 1997-06-10

Similar Documents

Publication Publication Date Title
SE9404468D0 (sv) Powder formulations
US5518998C1 (en) Therapeutic preparation for inhalation
IL95590A0 (en) Pharmaceutical compositions comprising salmeterol and fluticasone propionate
DE69203996D1 (de) Absorption von Kohlendioxid, das sich in dem Inatmungs- und Ausatmungsgas eines betäubten Patienten befindet.
DE60044789D1 (de) Verbesserungen an einem Inhalationsgerät
DE3650315D1 (de) Cyancrotonsäureamidverbindung als Arzneimittel mit immunmodulierenden Eigenschaften.
CA2136740A1 (en) Arrangement and method for dispensing preservative-free nasal sprays and similar preparations
NL193930B (nl) Inhaleerinrichting met verpakking voor medicijn in poedervorm alsmede een dergelijke medicijnverpakking.
FI935464A (fi) Klorfluorkolfria aerosolformulationer
IL142011A0 (en) Stable concentrated insulin preparations for pulmonary delivery
FI930912A0 (fi) Nya cyklosporiner
GB9410817D0 (en) Medicaments
ATE113477T1 (de) Therapeutisch wirksames stoffgemisch aus glutathion- und anthocyan-verbindungen.
AU653861B2 (en) Respiratory disease vaccine for cats
AU634584B2 (en) Aroyl-ureas
EP0214281A4 (en) PROTEIN-ABSORBING AGENTS.
EP0191814A4 (en) ABSORPTION IMPROVERS FOR PROTEINS.
ITPR910054A0 (it) Miscelatore per autorespiratore ad uso medicale,particolarmente per camera iperbarica.
ES290230U (es) Camara de inhalacion perfeccionada para aerosoles de uso te-rapeutico
RU93002216A (ru) Ингалятор
TH16088A (th) สูตรผสมสำหรับการสูดดม